Calcium Folate is the calcium salt of the vitamin folic acid which is involved in the metabolism of proteins and DNA. Folic acid is sensitive to acidic-oxidative conditions and, in the presence of Ca+2 as well, is metabolically transformed into pterins and calcium pterins. This pilot observational study describes the use of CaFolate-derived CaPterins in the treatment of certain immune-related ailments. Thirty-one patients with various immune-associated disorders were directed to take ad libitum 25-76 mg of CaFolate (300-900 µg folic acid equivalent) orally per day, and to collect personal and medical assessments. The users reported no flu/colds (13/13 reporting none during the cold and flu season), greater energy/stamina (8/8 reporting increased), less arthritis pain (10/11 reporting improvement), and diminished mouth sores due to chemotherapy (2/2 reporting significant clearance). These observational findings identify certain clinical endpoints for future matched group, randomized, double-blind, placebo-controlled clinical trials.
Calcium Folate, Calcium Pterin, Folic Acid-Based Immunotherapeutics, Immune-Related Disorders, Pterins
P. Moheno, Calcium Pterin-6-carboxylate (CaPterin-6-COOH) as a Novel Immuno-Therapeutic, in: US Provisional Patent application, SanRx Pharmaceuticals, Inc., USA, 2014.
I. Ziegler, U. Hamm, J. Berndt, Participation of pterins in the control of lymphocyte stimulation and lymphoblast proliferation, Cancer Res, 43 (1983a) 5356-5359.
I. Ziegler, U. Hamm, J. Berndt, Pterins as functioning constituents of the lymphokine system, In: Curtius, H.Ch., Pfleiderer, W., Wachter, H. (Eds), Biochemical and Clinical Aspects of Pteridines, 2 (1983b) 185-193.
B. Stea, R.M. Halpern, B.C. Halpern, R.A. Smith, Urinary excretion levels of unconjugated pterins in cancer patients and normal individuals, Clin Chim Acta, 113 (1981) 231-242.
P. Moheno, W. Pfleiderer, A.G. DiPasquale, A.L. Rheingold, D. Fuchs, Cytokine and IDO metabolite changes effected by calcium pterin during inhibition of MDA-MB-231 xenograph tumors in nude mice, Int J Pharm, 355 (2008) 238-248.
P. Moheno, W. Pfleiderer, D. Fuchs, Plasma cytokine concentration changes induced by the antitumor agents dipterinyl calcium pentahydrate (DCP) and related calcium pterins, Immunobiology, 214 (2009) 135-141.
P. Moheno, Calcium pterin as an antitumor agent, Int J Pharm, 271 (2004) 293-300.
P. Moheno, J. Morrey, D. Fuchs, Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice, J Transl Med, 8 (2010) 32.
S.E. Nikoulina, D. Fuchs, P. Moheno, Effect of Orally Administered Dipterinyl Calcium Pentahydrate (DCP) on Oral Glucose Tolerance in DIO Mice, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 5 (2012) 43-47.
I.G. Sakala, C.S. Eickhoff, A. Blazevic, P. Moheno, R.F. Silver, D.F. Hoft, Dipterinyl Calcium Pentahydrate Inhibits Intracellular Mycobacterial Growth in Human Monocytes via the C-C Chemokine MIP-1beta and Nitric Oxide, Infect Immun, 81 (2013) 1974-1983.
C. Winkler, K. Schroecksnadel, P. Moheno, E. Meerbergen, H. Schennach, D. Fuchs, Calcium-pterin suppresses mitogen-induced tryptophan degradation and neopterin production in peripheral blood mononuclear cells, Immunobiology, 211 (2006) 779-784.
O.H. Lowry, O.A. Bessey, E.J. Crawford, Photolytic and enzymatic transformations of pteroylglutamic acid, J Biol Chem, 180 (1949) 389-398.
N.I.o. Health, Folate: Dietary Supplement Fact Sheet, in, 2012.